Samantha Justice
Family · Tishomingo, MSNPI 1013267152
Payments from drug & device makers
Across 277 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$472
- Pfizer$218
- AstraZeneca$214
- Novo Nordisk$209
- Lilly USA, LLC$185
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,976100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 142 | $1,545 |
| Amgen(2 entities) | 27 | $472 |
| Pfizer | 12 | $218 |
| AstraZeneca | 7 | $214 |
| Novo Nordisk | 14 | $209 |
| Lilly USA, LLC | 11 | $185 |
| Boehringer Ingelheim | 10 | $178 |
| Esperion Therapeutics, Inc. | 6 | $102 |
| Bayer | 5 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Johnson & Johnson(2 entities) | 4 | $79 |
| Xeris Pharmaceuticals, Inc. | 3 | $73 |
| GSK | 5 | $71 |
| Abbott | 3 | $70 |
| Novartis | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $60 |
| Scynexis, Inc. | 2 | $45 |
| IBSA Pharma Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Genentech USA, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,976 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 790 | $1,523,687 |
| EliquisApixaban | 489 | $778,807 |
| MounjaroTirzepatide | 315 | $552,299 |
| JardianceEmpagliflozin | 330 | $531,820 |
| FarxigaDapagliflozin Propanediol | 266 | $399,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 206 | $351,208 |
| XareltoRivaroxaban | 251 | $296,967 |
| Tresiba Flextouch U-200Insulin Degludec | 130 | $241,608 |
| EntrestoSacubitril/Valsartan | 114 | $166,308 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 107 | $155,204 |
| RybelsusSemaglutide | 61 | $131,625 |
| Xigduo XrDapaglifloz Propaned/Metformin | 92 | $126,736 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $121,161 |
| LinzessLinaclotide | 117 | $119,693 |
| Enbrel SureclickEtanercept | 12 | $108,642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $209 | $1,750,376915 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy, Jentadueto Xr | $178 | $797,906519 claims |
| PfizerEliquis | $218 | $778,807489 claims |
| Lilly USA, LLCMounjaro, Trulicity | $185 | $626,518366 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $214 | $464,124304 claims |
| AbbVieLinzess, Creon, Rinvoq, Vraylar, Ubrelvy | $1,545 | $452,706225 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $71 | $385,987241 claims |
| Johnson & JohnsonXarelto | $79 | $296,967251 claims |
| NovartisEntresto | $64 | $166,308114 claims |
| MerckJanuvia, Janumet Xr | $14 | $121,94482 claims |
| AmgenOtezla | $472 | $92,24218 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $28 | $44,60246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Tishomingo
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.